NEW YORK – The US Food and Drug Administration on Monday released guidance outlining how developers of companion diagnostics for personalizing cancer therapies can broaden the indication for a test so that it references a group of similar drugs instead of a specific treatment.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.